Stress and non-clinical anxiety — peptide, drug, supplement, and lifestyle options compared

This guide is for the subjective experience that most adults call "feeling stressed" or "running anxious" — chronic baseline elevation, performance anxiety, ruminative thinking, sleep-onset worry, sympathetic over-tone — that is real and quality-of-life-relevant but does not meet the diagnostic threshold for generalized anxiety disorder, panic disorder, or post-traumatic stress.

The reason this distinction matters: the evidence base for treating diagnosed anxiety disorders is large and well-established. SSRIs, CBT, and benzodiazepines (short-term) have Tier 1 RCT support for those conditions. The evidence base for treating sub-clinical chronic stress is much messier — partly because the population is heterogeneous (people who would benefit from sleep optimization, people who would benefit from cardio, people who would benefit from removing alcohol, and people with genuine subthreshold anxiety all end up in the same trials), and partly because the interventions that work best are not pharmaceutical.

This guide is structured around a load-bearing observation: the highest-leverage interventions for non-clinical anxiety are not drugs. Sleep, cardio, breath / nervous-system practices, caffeine modulation, alcohol minimization, and ruminative-thinking interventions (CBT-derived or meditation-derived) each have stronger evidence and more durable effects than any pharmacological option below. Every pharmacological row is most defensible as a short-term adjunct or a bridge while the upstream work gets dialed in.

For people whose anxiety meets clinical thresholds — daily impairment, panic attacks, suicidal ideation, can't work, can't sleep — this guide is not the right one. See a clinician.

The comparison

Option	Evidence tier (for non-clinical anxiety)	Effect type	Time to outcome	Cost / month (US, 2026 est.)	Side effects	Dependence / rebound	Who should consider	Who should skip
Cardio (Z2 + occasional Z4/5), 150+ min/wk	Tier 1 (large literature on exercise + anxiety)	Reduced baseline sympathetic tone; improved sleep; HRV improvement	4–12 weeks of sustained practice	$0–100	Soreness; injury risk if escalated too fast	None	Everyone	No one. Even alongside other interventions.
Sleep optimization (7+ hours, consistent schedule, dark/cool)	Tier 1 (sleep–anxiety bidirectional)	Reduced amygdala reactivity; improved emotional regulation	2–6 weeks	$0–200	None	None	Everyone with anxiety + suboptimal sleep	No one
Caffeine modulation (cap at 200–400 mg, none after noon)	Tier 1 (caffeine–anxiety dose-response is well-established)	Reduced background activation; improved sleep	Same-day improvement; 1–2 weeks to stabilize	Saves money	Headaches first 3–7 days if abrupt taper	None at modulation; mild withdrawal at full cessation	Heavy coffee/preworkout users with anxious / wired baseline	No one — even non-anxious people benefit from late-afternoon caffeine cessation
Alcohol minimization	Tier 1 (alcohol disrupts sleep architecture; rebound anxiety 12–24 hr post)	Reduced rebound sympathetic activation; better sleep	1–4 weeks	Saves money	None at minimization; structured AUD-care if dependent	None	Anyone using regular alcohol with anxiety substrate	Diagnosed AUD (needs clinical support, not just self-cessation)
Breath / nervous-system practices (slow exhale, box breathing, 5-min daily)	Tier 2 (positive but heterogeneous; effect-size estimates from ~0.3 to ~0.8 across trial designs)	Acute parasympathetic activation; with practice, more accessible baseline	Acute: minutes. Trait: 4–12 weeks.	$0	None	None	Everyone interested in a no-cost-no-pharmacology intervention	No one
Meditation / mindfulness practice (10–20 min daily)	Tier 1–2 (Goyal 2014 JAMA Intern Med meta-analysis: moderate effect on anxiety symptoms)	Trait reduction in ruminative thinking; reduced amygdala reactivity (long-term meditators)	8–16 weeks for trait shift	$0–20 (apps)	None	None	Anyone willing to do a daily practice for 8+ weeks	Anyone using meditation to avoid clinical care for a clinical condition
CBT (cognitive behavioral therapy)	Tier 1 (anxiety disorders); Tier 2 (subthreshold anxiety)	Cognitive-pattern restructuring; durable	8–16 weeks of structured course	$1500–3000 in-person; $0–500 app-delivered	None	None — gains persist	Anyone with ruminative-thinking pattern or cognitive distortions	No one with chronic anxiety
L-theanine 200–400 mg	Tier 2 (small effect; better evidence for caffeine-tempering than for anxiety reduction per se)	Mild relaxation; smooths caffeine activation	Acute (within 30–60 min)	$10–20	Minimal	None	Stacked with caffeine; "wired" presentation; pre-event nerves	Severe / clinical anxiety (effect size too small)
Ashwagandha (KSM-66 or Sensoril, 300–600 mg)	Tier 2 (multiple small positive RCTs; replication mixed)	Cortisol reduction; subjective stress	4–8 weeks	$15–30	Mild GI; rare thyroid-stimulation cases; hepatotoxicity case reports (uncommon)	Low	Subjective chronic-stress complaint; willing to try a supplement-tier intervention	Pregnancy (uterine effects); thyroid disorders without consultation; rare hepatotoxicity case awareness
Magnesium glycinate 200–400 mg	Tier 2 for anxiety; Tier 1 for sleep adjunct	Mild relaxation; GABA cofactor; sleep quality	1–4 weeks	$10–20	Loose stools at high doses	None	Muscular tension; "wired" baseline; suboptimal sleep	Renal impairment without consultation
Selank (intranasal)	Tier 2 (Russian RCT literature — Zozulya 2008 and follow-ups for GAD-pattern); Tier 3 for non-clinical use	Anxiolytic without sedation or dependence; modulates GABA + serotonin + neurotrophic signaling without classical pharmacology	1–4 weeks	$30–50 research suppliers	Mild nasal irritation; transient headache; rare GI	None reported in available literature; cycling is convention not evidence-driven	Curious about non-sedating anxiolytic; tolerates non-Western primary literature; runs structured self-experiment	Anyone expecting Western RCT-grade evidence; clinical-threshold anxiety (use evidence-based clinical pathways)
Beta-blockers (propranolol, short-term)	Tier 1 for performance anxiety	Suppresses physical symptoms (tachycardia, tremor); does not address cognitive anxiety	Acute (30–60 min)	$10–30 with prescription	Hypotension; bronchoconstriction in asthma; fatigue	Low dependence; rebound possible at high chronic doses	Performance anxiety (public speaking, audition); short-term acute use	Asthma; existing hypotension; chronic anxiety pattern (wrong tool — propranolol masks symptoms without addressing pattern)
SSRIs (sertraline, escitalopram, etc.)	Tier 1 for diagnosed anxiety disorders; Tier 3 for sub-clinical	Reduced baseline anxiety; reduced rumination	4–12 weeks for full effect	$10–30 (generic)	GI, sexual side effects, emotional blunting, weight gain, withdrawal on stop	High discontinuation syndrome at stop	Diagnosed GAD, panic disorder, or comorbid depression; this is a clinical conversation	Sub-clinical anxiety where lifestyle work has not been attempted; people unwilling to commit to 6+ months minimum
Benzodiazepines	Tier 1 acute anxiolytic; Tier 1 for harm profile	Acute reduction; rapid onset	Acute (15–60 min)	$10–40 with prescription	Cognitive impairment; falls in elderly; complex sleep behaviors at higher doses	High dependence; severe withdrawal	Acute crisis bridge; short-term flight anxiety; pre-procedure	Chronic use of any kind. Use creates the condition it's intended to treat over 6+ months.

The top 7 rows of this table are not really competing with the bottom rows — they are the floor that determines whether anything else works. The Selank and beta-blocker rows are the narrow places where pharmacological intervention has the best risk-benefit profile in this population. The SSRI and benzodiazepine rows are properly clinical conversations.

This guide carries the public comparison. The member continuation walks the deeper case for each option, the case for Selank specifically in the harm-reduction frame, and the founder's view on what to actually do.